Moderna Resolves LNP Patent Disputes with Arbutus, Genevant for $950 Million, Eliminating Key Financial Risk

has agreed to pay $950 million to Arbutus Biopharma Corp. and Genevant Sciences GmbH, settling all worldwide litigation related to the lipid nanoparticle (LNP) delivery technology crucial for its Covid-19 vaccine.

This significant payment resolves claims that Moderna infringed on patents owned by Arbutus and Genevant concerning the tiny fat bubbles used to deliver its mRNA shot. Crucially for the struggling vaccine maker, the settlement eliminates any future royalty obligations on both existing and future vaccines utilizing this technology.

The resolution removes a substantial financial overhang and legal uncertainty, providing clarity on a key intellectual property component of Moderna's platform. This move allows Moderna to focus on its pipeline and commercial efforts without the burden of ongoing litigation and potential future royalty payments, which could positively impact its long-term financial outlook and investor confidence.